Journal article
Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial
Otolaryngology-head and neck surgery, Vol.170(5), pp.1430-1441
05/2024
DOI: 10.1002/ohn.670
PMCID: PMC11060929
PMID: 38415855
Abstract
To determine the positivity rate of congenital cytomegalovirus (cCMV) testing among universal, hearing-targeted CMV testing (HT-cCMV) and delayed targeted dried blood spot (DBS) testing newborn screening programs, and to examine the characteristics of successful HT-cCMV testing programs.
Prospective survey of birth hospitals performing early CMV testing.
Multiple institutions.
Birth hospitals participating in the National Institutes of Health ValEAR clinical trial were surveyed to determine the rates of cCMV positivity associated with 3 different testing approaches: universal testing, HT-cCMV, and DBS testing. A mixed methods model was created to determine associations between successful HT-cCMV screening and specific screening protocols.
Eighty-two birth hospitals were surveyed from February 2019 to December 2021. Seven thousand six hundred seventy infants underwent universal screening, 9017 infants HT-cCMV and 535 infants delayed DBS testing. The rates of cCMV positivity were 0.5%, 1.5%, and 7.3%, respectively. The positivity rate for universal CMV screening was less during the COVID-19 pandemic than that reported prior to the pandemic. There were no statistically significant drops in positivity for any approach during the pandemic. For HT-cCMV testing, unique order sets and rigorous posttesting protocols were associated with successful screening programs.
Rates of cCMV positivity differed among the 3 approaches. The rates are comparable to cohort studies reported in the literature. Universal CMV prevalence decreased during the pandemic but not significantly. Institutions with specific order set for CMV testing where the primary care physician orders the test and the nurse facilitates the testing process exhibited higher rates of HT-cCMV testing.
Details
- Title: Subtitle
- Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial
- Creators
- Quinn T Orb - University of UtahMegan PeschChelsea M Allen - University of UtahAshlea Wilkes - University of UtahIram AhmadKristan AlfonsoStephanie Moody AntonioLeena Mithal BhattacharyaJennifer V BrinkmeierDaniela CarvalhoDylan ChanAlan G ChengDavid ChiMichael CohenChristopher Michael DiscoloCarlos DuranJohn GermillerLaura GibsonEli GrunsteinGail HarrisonKenneth LeeKaren HawleyStephan KohlhoffAnn MelvinCarol MacArthurMichel NassarLaura NeffPhayvanh PechaChristine SalvatoreScott SchoemFrank VirginJames SaundersMark SchleissRichard J H SmithSunil SoodAlbert H Park - University of UtahValEAR Study Group, Worcester, Massachusetts, USA
- Resource Type
- Journal article
- Publication Details
- Otolaryngology-head and neck surgery, Vol.170(5), pp.1430-1441
- DOI
- 10.1002/ohn.670
- PMID
- 38415855
- PMCID
- PMC11060929
- NLM abbreviation
- Otolaryngol Head Neck Surg
- eISSN
- 1097-6817
- Language
- English
- Electronic publication date
- 02/28/2024
- Date published
- 05/2024
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Molecular Physiology and Biophysics; Anatomy and Cell Biology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Otolaryngology; Internal Medicine
- Record Identifier
- 9984563557802771
Metrics
10 Record Views